Abstract:Dendritic cells (DCs) have attracted considerable attention as potential targets for the development of therapeutic cancer vaccines. This approach generally involves the differentiation of DCs from autologous, patient-derived monocytes, followed by ex vivo DC exposure to an appropriate source of tumour associated antigens (TAAs) or neoantigens in the context of immunostimulatory maturation cocktails, and culminating with the reinfusion of these stimulated DCs back into the patient [1, 2]. Accumulating clinical evidence demonstrates that this approach often promotes some degree of TAA/neoantigen-specific T cell driven immunity in patients [3, 4]. However, the success of such therapeutic regimens in the clinic has been inconsistent, raising an acute need for innovation in this field. This is especially relevant for tumours that display an immunosuppressive phenotype, distinguished by low T cell infiltration but high myeloid content, since these are almost completely resistant to all the current immunotherapies [5, 6]. Although the field of therapeutic DC vaccination has made vast progress through a plethora of preclinical and clinical research, DC vaccines still need to move towards a 'next-generation' that is clinically useful [7, 8]. Currently, there are at least three areas in which the development of next-generation DC vaccines is progressing: (1) utilization of specific DC subsets [9], (2) the source of antigen entailing either personalized neoantigens or more immunogenic forms of cancer cell death to allow more effective antigen "pulsing" of DCs, and (3) the stimulatory factors used for activating DCs [10, 11]. Besides, for DC vaccines to succeed in the future, it is important to understand the exact immunological resistance pathway limiting its efficacy. The latter area has received less attention than the former three. Moreover, the gaps between preclinical and clinical settings from the angle of cross-species translational immunology have been seldom addressed. Next, we wanted to understand the in vivo mechanism of action as well as possible mechanisms behind the failure of a DCvax-IT formulation. Hence, we created a preclinical version of DCvax-IT using a combination of immunogenic cancer cell death (ICD) with IFNβ that faithfully recapitulated the clinical immunogenic DC trajectory in terms of an upregulated antigen presentation, type I IFN response and pro-inflammatory immuno-cytokine profile. Indeed, this DCvax-IT favoured type I IFN responses over macrophage-like and mreg DC-like phenotypes. In vivo, DCvax-IT showed a high capacity at inducing preventive anticancer immunity but failed to induce a curative immunity against murine immunosuppressive tumours. This, despite the observations that, DCvax-IT was successfully reaching the lymph node (LN). This hinted at a potential (hitherto unknown) resistance mechanism that might be limiting T cell activation following anticancer vaccination.

Next-generation cancer vaccines and emerging immunotherapy combinations

Cancer vaccines: the next immunotherapy frontier

Turning the corner on therapeutic cancer vaccines

Therapeutic cancer vaccines: advancements, challenges, and prospects

Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy

Advances in Cancer Vaccine Research

Cancer Vaccines: Promising Therapeutics or an Unattainable Dream

Cancer Vaccines: Recent Insights and Future Directions

Recent progress in cancer vaccines and nanovaccines

Advancing Clinical Applications in Cancer Treatment

Cancer vaccines: past, present and future; a review article

The next chapter in immunotherapy and radiation combination therapy – cancer-specific perspectives

Therapeutic Vaccines for Cancer Immunotherapy

Are we getting closer to a successful neoantigen cancer vaccine?

Next-generation DC vaccines with an immunogenic trajectory against cancer: therapeutic opportunities vs. resistance mechanisms

Next-generation combination approaches for immune checkpoint therapy

Roadmap to next-generation cancer vaccines

Cancer immunotherapy: broadening the scope of targetable tumours

Cancer neoantigens as potential targets for immunotherapy

Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities